Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery

Canadian Journal of Anesthesia

Volumn 54, Issue 2, 2007, Pages 107-113

  Bar Yosef, Shahar ^a   Cozart, Heidi B ^a   Phillips Bure, Barbara ^a   Mathew, Joseph P ^a   Grocott, Hilary P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOTTING TIME; BODY WEIGHT; CARDIOPULMONARY BYPASS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; THROMBOSIS;

EID: 33947722601     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022006     Document Type: Article

References (34)

1. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999; 91: 1122-51.
2. Anderson EF. Heparin resistance prior to cardiopulmonary bypass. Anesthesiology 1986; 64: 504-7.
3. Cloyd GM, D'Ambra MN, Akins CW. Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1987; 94: 535-8.
4. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994; 57: 1211-6.
5. Levy JH. Heparin resistance and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth 2004; 18: 129-30.
6. Chung F, David TE, Watt J. Excessive requirement for heparin during cardiac surgery. Can Anaesth Soc J 1981; 28: 280-2.
7. Mabry CD, Read RC, Thompson BW, Williams GD, White HJ. Identification of heparin resistance during cardiac and vascular surgery. Arch Surg 1979; 114: 129-34.
8. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: 505-14.
9. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2: 581-4.
10. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997; 85: 498-506.
11. Dietrich W, Braun S, Spannagl M, Richter JA. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg 2001; 92: 66-71.
12. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90: 1076-9.
13. Sabbagh AH, Chung GK, Shuttleworth P, Applegate BJ, Gabrhel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg 1984; 37: 466-8.
14. Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123: 213-7.
15. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70: 873-7.
16. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102: 276-84.
17. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983; 85: 346-53.
18. Linden MD, Schneider M, Baker S, Erber WN. Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2004; 18: 131-5.
19. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-1601.
20. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292: 89-96.
21. Weitz JL. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
22. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 suppl): 188S-203S.
23. Wang JS, Lin CY, Hung WT, Thisted RA, Karp RB. In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg 1992; 104: 1135-40.
24. Ranucci M, Isgro G, Cazzaniga A, et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199-204.
25. Ranucci M, Isgro G, Cazzaniga A, Soro G, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999; 14: 437-42.
26. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994; 58: 799-804.
27. Grichnik K, Newman M, Sanderson I, Slaughter T, White W, Reves J. Does age influence the coagulation response to a dose of heparin? Anesth Analg 1999; 88: SCA31.
28. Vuylsteke A, Mills RJ, Crosbie AE, Burns TI, Latimer RD. Increased pre-operative platelet counts are a possible predictor for reduced sensitivity to heparin. Br J Anaesth 2000; 85: 896-8.
29. Horne MK 3rd, Chao ES. Heparin binding to resting and activated platelets. Blood 1989; 74: 238-43.
30. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380-5.
31. Cohen JA. Activated coagulation time method for control of heparin is reliable during cardiopulmonary bypass. Anesthesiology 1984; 60: 121-4.
32. Marciniak E, Gora-Maslak G. Enhancement by heparin of thrombin-induced antithrombin III proteolysis: its relation to the molecular weight and anticoagulant activity of heparin. Thromb Res 1982; 28: 411-21.
33. Brinks HJ, Weerwind PW, Bogdan S, Verbruggen H, Brouwer MH. Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass? Perfusion 2001; 16: 3-12.
34. Shore-Lesserson L, Manspeizer HE, Bolastig M, Harrington D, Vela-Cantos F, DePerio M. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time. Anesth Analg 2000; 90: 813-8.